Background: Mussel adhesive protein (MAP) is extracted from the mycelial glands of marine mussels. It has anti-inflammatory properties and may relieve skin itching and other symptoms. Aims:Based on the anti-inflammatory effect of MAP, this study was designed to treat sensitive skin (SS) using MAP delivered by skin microneedling.Patients/methods: Twenty-three Chinese female patients with SS were enrolled.Treatments were delivered three times at one-month intervals. Symptom improvement and recurrence rates, treatment safety, and patient satisfaction levels were evaluated.Results: After one course of treatment, 20 patients had a Symptom Score Reducing Index (SSRI) of >20%, with an effectiveness rate of 87%. At the end of treatment, all patients had an SSRI of >20%, and the effectiveness rate was 100%. Dryness, tightness, desquamation, flushing, burning, itching, and tingling improved. After treatment, the Clinical Erythema Assessment and Lesion Severity Index of Facial Telangiectasia scores were significantly decreased. Clinical photographs following treatment revealed improved erythema reaction and decreased capillary density. During treatment, the patients experienced mild pain and erythema and swelling reaction without exudation. Complications, such as pigmentation changes or scarring, were absent.Additionally, there were no cases of recurrence, and patient satisfaction levels were high. Conclusion:MAP combined with microneedling can help treat SS, showing satisfactory safety outcomes and high patient satisfaction.
Background Rosacea is a chronic inflammatory skin disease affecting the face, and the current treatment effect is not satisfactory. Based on the photomodulation of optimal pulse technology (OPT), we developed a novel treatment mode, namely, advanced OPT with low energy, three pulses, and long pulse width (AOPT‐LTL). Aims We aimed to explore the feasibility and underlying molecular mechanisms of AOPT‐LTL treatment in a rosacea‐like mouse model. Furthermore, we evaluated the safety and efficacy in patients with erythematotelangiectatic rosacea (ETR). Materials and methods Morphological, histological, and immunohistochemical analyses were used to investigate the efficacy and mechanisms of AOPT‐LTL treatment in the LL‐37‐induced rosacea‐like mouse model. Moreover, 23 patients with ETR were included and received different times of treatment at intervals of 2 weeks depending on the severity of their condition. The treatment effect was assessed by comparing clinical photographs at baseline, 1 week, and 3 months after treatment, combined with the red value, GFSS, and CEA scores. Results After the AOPT‐LTL treatment of the mice, we observed that the rosacea‐like phenotype, inflammatory cell infiltration, and vascular abnormalities were significantly ameliorated, and the expression of the core molecules of rosacea was significantly inhibited. In the clinical study, the AOPT‐LTL treatment exerted satisfactory therapeutic effects on erythema and flushing of ETR patients. No serious adverse events were observed. Conclusions AOPT‐LTL is a safe and effective method for the treatment of ETR.
Sensitive skin (SS) is a condition that mostly affects women in which the skin overreacts under physiological or pathological conditions, and mainly occurs on the face. It is characterized by the appearance of tingling, burning, itching, and tightness in response to various factors, but often lacks specific clinical signs. The number of SS patients is increasing day by day. According to epidemiological data, the global prevalence rate of SS has reached 40%. 1 However, most of the time the patients only experience discomfort without clinical signs. 2 The pathogenic mechanism of SS is a complex process, involving impaired epidermal barrier function, 2,3 the reaction to external stimuli is enhanced, 4 and cutaneous immune cells also play a crucial role
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.